ImmunoGen’s First ADC For Ovarian Cancer To Exceed Sales Expectations
Stellar Launch For Elahere
Executive Summary
ImmunoGen’s Elahere, the only antibody-drug conjugate approved for platinum-resistant ovarian cancer in the US, will produce better than anticipated sales for the first quarter of 2023, CEO Mark Enyedy hinted in a recent interview.